Skip to main content

LCD L39434: Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin

LCD L39434, Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin, is the Local Coverage Determination that CGS Administrators, LLC applies to claims from 2 states (KY, OH), effective 2026-03-05 and first in force 2023-02-19. The policy text runs 734 words, and its billing and coding article A59215 lists 372 ICD-10-CM codes that support medical necessity for 1 procedure code. 3 other contractor versions share this title, so the criteria depend on where the service is furnished. Counting every linked billing and coding article, this one lists 372 covered ICD-10-CM codes: 5 more codes than L39270 (Palmetto GBA, 367 codes, revised 2024-12-19) and 8 fewer codes than L39477 (Wisconsin Physicians Service Insurance Corporation, 380 codes, revised 2024-12-26).

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
CGS Administrators, LLC
States and territories
2
KY OH
Revision effective
2026-03-05
Original effective
2023-02-19
Policy text
734 words
Covered ICD-10 codes (articles)
372

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L39434
ContractContractorTypeStates
15102CGS Administrators, LLCMAC - Part BKY
15202CGS Administrators, LLCMAC - Part BOH
15101CGS Administrators, LLCMAC - Part AKY
15201CGS Administrators, LLCMAC - Part AOH

Billing and coding article A59215: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A59215 (Billing and Coding: Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

A59215: Billing and Coding: Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin (Billing and Coding, effective 2026-03-05)

Covered ICD-10-CM codes
372
1 group
Non-covered ICD-10-CM codes
0
Procedure codes listed
1
Full article
cms.gov record
First 24 covered ICD-10-CM codes in A59215
ICD-10-CMDescription (FY2027)
C81.00Nodular lymphocyte predominant Hodgkin lymphoma, unspecified site
C81.01Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of head, face, and neck
C81.02Nodular lymphocyte predominant Hodgkin lymphoma, intrathoracic lymph nodes
C81.03Nodular lymphocyte predominant Hodgkin lymphoma, intra-abdominal lymph nodes
C81.04Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.05Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C81.06Nodular lymphocyte predominant Hodgkin lymphoma, intrapelvic lymph nodes
C81.07Nodular lymphocyte predominant Hodgkin lymphoma, spleen
C81.08Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of multiple sites
C81.09Nodular lymphocyte predominant Hodgkin lymphoma, extranodal and solid organ sites
C81.10Nodular sclerosis Hodgkin lymphoma, unspecified site
C81.11Nodular sclerosis Hodgkin lymphoma, lymph nodes of head, face, and neck
C81.12Nodular sclerosis Hodgkin lymphoma, intrathoracic lymph nodes
C81.13Nodular sclerosis Hodgkin lymphoma, intra-abdominal lymph nodes
C81.14Nodular sclerosis Hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.15Nodular sclerosis Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C81.16Nodular sclerosis Hodgkin lymphoma, intrapelvic lymph nodes
C81.17Nodular sclerosis Hodgkin lymphoma, spleen
C81.18Nodular sclerosis Hodgkin lymphoma, lymph nodes of multiple sites
C81.19Nodular sclerosis Hodgkin lymphoma, extranodal and solid organ sites
C81.20Mixed cellularity Hodgkin lymphoma, unspecified site
C81.21Mixed cellularity Hodgkin lymphoma, lymph nodes of head, face, and neck
C81.22Mixed cellularity Hodgkin lymphoma, intrathoracic lymph nodes
C81.23Mixed cellularity Hodgkin lymphoma, intra-abdominal lymph nodes

Procedure codes: 38240.

Coverage indications, limitations and medical necessity

Background

Stem cell transplantation is a process in which stem cells are harvested from either a patient’s (autologous) or donor’s (Allogeneic) bone marrow or peripheral blood for intravenous infusion. Autologous stem cell transplantation (AuSCT) is a technique for restoring stem cells using the patient's own previously stored cells. AuSCT must be used to effect hematopoietic reconstitution following severely myelotoxic doses of chemotherapy (HDCT) and/or radiotherapy used to treat various malignancies. Allogeneic hematopoietic stem cell transplantation (HSCT) is a procedure in which a portion of a healthy donor's stem cells or bone marrow is obtained and prepared for intravenous infusion.

Allogeneic hematopoietic stem cell transplantation (HSCT) is a procedure in which a portion of a healthy donor's stem cells or bone marrow is obtained and prepared for intravenous infusion. Hematopoietic stem cells are multi-potent cells that give rise to all the blood cell types; these stem cells form blood and immune cells. A hematopoietic stem cell is a cell isolated from blood or bone marrow that can renew itself, differentiate to a variety of specialized cells, can mobilize out of the bone marrow into circulating blood, and can undergo programmed cell death, called apoptosis - a process by which cells that are unneeded or detrimental will self-destruct.

The Centers for Medicare & Medicaid Services (CMS) has clarified that bone marrow and peripheral blood stem cell transplantation is a process which includes mobilization, harvesting, and transplant of bone marrow or peripheral blood stem cells and the administration of high dose chemotherapy or radiotherapy prior to the actual transplant. When bone marrow or peripheral blood stem cell transplantation is covered, all necessary steps are included in coverage.

NCD 110.23 Stem Cell Transplantation includes for allogenic transplantation:

• Leukemia

• Aplastic Anemia

• Severe Combined Immunodeficiency disease (SCID)

• Wiskott-Aldrich Syndrome

Allogeneic HSCT is covered only for Medicare beneficiaries with the following indications when participating in an approved prospective clinical study meeting specific criteria under the Coverage with Evidence Development (CED) paradigm:

• Myelodysplastic Syndrome

• Multiple myeloma only for beneficiaries with Durie-Salmon Stage II or III multiple myeloma, or International Staging System (ISS) Stage II or Stage III multiple myeloma

• Myelofibrosis (MF) only for beneficiaries with Dynamic International Prognostic Scoring System (DIPSSplus) intermediate-2 or High primary or secondary MF; or

• Sickle cell disease (SCD) only for beneficiaries with severe, symptomatic SCD who participate in an approved prospective clinical study meeting specific criteria under the CED paradigm. (Please refer to CMS Publication 100-03, Medicare National Coverage Determinations (NCD) Manual , Chapter 1, Part 2, §110.23)

Per the NCD, “All other indications for stem cell transplantation not otherwise noted above as covered or non-covered remain at local Medicare Administrative Contractor discretion.”

Allogeneic hematopoietic cell transplantation, (HCT) has been increasingly used for a variety of hematologic neoplasm and non-malignant marrow disorders. Eligibility for Allogeneic HCT varies among institutions and is usually based on a case-by-case basis dependent upon a risk-benefit assessment, and the needs and wishes of the patient. 1

Although historically allogeneic HCT was offered to patients who had exhausted all other treatment modalities, currently the decision to perform a transplant is dependent upon an assessment if the transplant will offer an outcome superior to other treatment options. 1

The CMS National Coverage Determination (NCD 110.23) for Stem Cell Transplantation describes nationally covered indications for stem cell transplant, the details of which will not be repeated within this policy. This policy describes additional locally covered indications for Allogeneic stem cell for primary refractory or relapsed Hodgkin's and non-Hodgkin's lymphoma with B-cell or T-cell origin, for whom there are no other curative intent options, and are medically necessary.

Multiple other disorders are under investigation as part of clinical trials and are not covered unless the clinical trial meets the criteria of NCD 310.1 Routine Costs in Clinical Trials.

This policy describes additional locally covered indications for Allogeneic stem cell for primary refractory or relapsed Hodgkin's and non-Hodgkin's lymphoma with B-cell or T-cell origin, for whom there are no other curative intent options, and are medically necessary.

Coverage Indications, Limitations, and/or Medical Necessity

Allogenic hematopoietic cell transplant is considered reasonable and necessary when:

• Patient has primary refractory or relapse of Hodgkin's or non-Hodgkin's lymphoma with B-cell or T-cell origin

• Pre-transplantation assessment indicates good function status, low-comorbidities and patient is candidate for transplantation based on risk assessment

• There are no other treatment options available with curative intent

Summary of evidence (opening)

Shah et al. studied matched cohorts of patients 1 over 64 (N = 446) and the other patients aged 55-64 (n-1183) who had non-Hodgkin’s lymphoma. 21 In a multivariant analysis, the 4-year probabilities of relapse or progression, progression free survival, and overall survival were only different in non-relapse mortality with an increased mortality in the older group. There were no significant differences in the other measures. Their conclusion was that “Age alone should not determine allo-HCT eligibility in NHL.”

Muffly et al. reviewed the use of allo-HCT in patients 70 and over as reported to the transplant registry. They found that 1,106 patients ≥70 years underwent HCT across 103 transplant centers. 3 The number and proportion of allografts performed in this population rose markedly over the past decade, accounting for 0.1% of transplants in 2000 to 3.85% (N = 298) in 2013. Acute myeloid leukemia and myelodysplastic syndromes represented the most common disease indications. Two-year OS and PFS significantly improved over time (OS: 26% [95% confidence interval (CI), 21% to 33%] in 2000-2007 to 39% [95% CI, 35% to 42%] in 2008-2013, P P = 0.003). Two-year TRM ranged from 33% to 35% and was unchanged over time ( P = 0.54). Multivariable analysis of OS in the modern era of 2008-2013 revealed higher comorbidity by HCT comorbidity index ≥3 (hazard ratio [HR], 1.27; P = 0.006), umbilical cord blood graft (HR, 1.97; P = 0.0002), and myeloablative conditioning (HR, 1.61; P = 0.0002) as adverse factors.

They concluded that over the past decade, utilization and survival after allogeneic transplant have increased in patients ≥70 years. Select adults ≥70 years with hematologic malignancies should be considered for transplant. They also state that allo-HCT is not the only therapeutic option available to older patients with relapsed/refractory or high-risk NHL. The intent of our analysis is not to prove superiority of allo-HCT in older NHL patients relative to other available tools (e.g., novel agents, autologous HCT, gene-modified T-cell therapies). Rather, we aim to demonstrate that, in any given NHL patient 2:65 years old, if after consideration of multiple variables, the treating physician has decided that allo-HCT is the next best therapy, an arbitrary age cutoff and lack of third-party (e.g., CMS) reimbursement should not remain a barrier against transplantation. Our study utilizing a large contemporary dataset suggests that survival outcomes of such Medicare-age eligible patients are not dramatically inferior to a decade-younger patient cohort undergoing similar allo-HCT procedures.

Majhail et al. published the guidelines for autologous and Allogeneic hematopoietic cell transplant from the American Society for Blood and Marrow Transplantation. 4 The guidelines state that “age by itself should not be a contraindication to transplantation in patients who may benefit from this procedure. Selected older patients with

The contractor cites 6 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2023-02-19
Current revision effective
2026-03-05
Last reviewed by the contractor
2026-02-26
MCD version
8

The contractor lists 2 National Coverage Determinations as related: NCD 110.23 Stem Cell Transplantation (Formerly 110.8.1), NCD 310.1 Routine Costs in Clinical Trials. Where an NCD speaks, it controls; the LCD can only address what the NCD leaves open.

Other related documents: A59289 (Response to Comments).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the CGS Administrators, LLC hub lists every other active policy from the same contractor.

The same policy title at other contractors

Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L39434 cover?

Stem cell transplantation is a process in which stem cells are harvested from either a patient’s (autologous) or donor’s (Allogeneic) bone marrow or peripheral blood for intravenous infusion. Autologous stem cell transplantation (AuSCT) is a technique for restoring stem cells using the patient's own previously stored cells. AuSCT must be used to effect hematopoietic reconstitution following severely myelotoxic doses… The full 734-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L39434 apply to?

CGS Administrators, LLC applies it to Medicare claims in 2 states: KY, OH. It binds only that contractor; 3 other contractor versions of this title govern other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L39434?

The companion billing and coding article A59215 lists 372 ICD-10-CM codes in 1 group that support medical necessity; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L39434?

A denial under LCD L39434 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A59215's 372 covered diagnosis codes, then file a redetermination with CGS Administrators, LLC within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.